吉贝尔(688566.SH)：2025年度净利润2.59亿元，同比增加17.94%

Core Viewpoint - The company reported a positive performance for the fiscal year 2025, with significant increases in both revenue and net profit, indicating strong operational health and growth potential in its product lines [1] Financial Performance - The company achieved total operating revenue of 965 million yuan, representing a year-on-year increase of 7.63% [1] - The net profit attributable to the parent company's shareholders was 259 million yuan, reflecting a year-on-year increase of 17.94% [1] Operational Highlights - The company has strengthened team building and market development, contributing to the growth in both revenue and net profit [1] - Sales revenue from the main product, Niquilol tablets, has maintained a rapid growth trend [1] Research and Development - The company is actively advancing the development of new drugs, including the antidepressant JJH201501 and the anti-tumor drug JJH201601 [1] - The Phase III clinical trial for the antidepressant JJH201501 has been successfully completed, while the Phase IIa clinical trial for the anti-tumor drug JJH201601 is progressing smoothly [1] Incentive Mechanism - To further establish and improve the company's long-term incentive mechanism, a restricted stock incentive plan for 2025 has been formulated and implemented [1] - The share-based payment expenses for the reporting period amounted to 23.5064 million yuan (unaudited, with final figures subject to the audited annual report) [1]